Paloma Partners’s Voyager Therapeutics VYGR Stock Holding History

Paloma Partners’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-16,500	Closed	-$155K	–	1975
2018 Q4	$155K	Buy	+16,500	New	+$212K	﹤0.01%	1084

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Paloma Partners's VYGR Position: Q1 2019 in Review

Paloma Partners sold out of Voyager Therapeutics (VYGR) in Q1 2019, closing a stake of 16,500 shares — an estimated $155K sold.

Paloma Partners first reported a position in VYGR in Q4 2018 and held it in 1 quarter. The position peaked at $155K in Q4 2018. 111 funds tracked by Wall St. Rank hold VYGR as of Q1 2019.

Paloma Partners reported no remaining Voyager Therapeutics position as of Q1 2019 after selling out during the quarter.
Paloma Partners sold 16,500 Voyager Therapeutics shares in Q1 2019, an estimated $155K.
Paloma Partners first reported a position in Voyager Therapeutics in Q4 2018 and held it in 1 quarter.
Paloma Partners's Voyager Therapeutics position peaked at $155K in Q4 2018.
111 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.